Leerink raises Ionis Pharmaceuticals target to $122
Leerink Partners analyst Mani Foroohar maintained an Outperform rating on Ionis Pharmaceuticals and raised the price target to $122 from $114.
*this image is generated using AI for illustrative purposes only.
Leerink Partners analyst Mani Foroohar has maintained an Outperform rating on Ionis Pharmaceuticals (NASDAQ: IONS) while raising the price target to $122 from $114. The adjustment reflects a revised outlook on the company's valuation and market performance.
Rating and Price Target Details
The research note highlights the firm's continued confidence in Ionis Pharmaceuticals despite the shift in price targets. The new target of $122 represents an increase over the prior estimate of $114.
| Metric | Value |
|---|---|
| Rating | Outperform |
| Previous Price Target | $114 |
| New Price Target | $122 |
The updated guidance provides investors with a new benchmark for the stock's potential trajectory.
What specific catalysts or data readouts are expected to drive the stock toward the new $122 price target?
How might this revised valuation impact investor sentiment regarding Ionis' pipeline progression?
Could this price target adjustment signal a broader trend of increased optimism for the biotech sector?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
